HealthRx.com

Joe Rogan and TRT: The Documented Public Record

By
Published Updated Last reviewed
Hormone therapy clinical care image for Joe Rogan and TRT: The Documented Public Record
Clinical image for Joe Rogan and TRT: The Documented Public Record Image: HealthRX.com clinical image

The Public Record: What Joe Rogan Has Actually Said

Joe Rogan first began discussing testosterone replacement therapy on his podcast in the early 2010s. By his own repeated admission across hundreds of episodes, he has used exogenous testosterone under physician supervision since his late 30s or early 40s. In a 2018 episode with Dr. Mark Gordon (episode #1056), Rogan stated plainly that he uses TRT and has for years. He reiterated this in conversations with guests including Dr. Andrew Huberman, Dr. Peter Attia, and Dr. Rhonda Patrick.

Rogan has been consistent: he frames TRT as a medical decision made in consultation with a physician, not a performance-enhancing shortcut. On multiple episodes he has described getting regular bloodwork and adjusting his protocol based on lab values.

Beyond testosterone, Rogan has publicly discussed:

  • Human growth hormone (HGH): Confirmed use on multiple episodes. He has described using HGH and discussed its effects on recovery and body composition with guests like Dr. Gordon and comedian/training partner Ari Shaffir.
  • BPC-157: Rogan has mentioned using this peptide for injury recovery, particularly in the context of joint and tendon healing. He discussed BPC-157 in detail during episode #1282 with Dr. Andrew Weil and in several clips that circulated widely on YouTube.
  • NAD+ infusions: Confirmed. Rogan has described receiving intravenous NAD+ and called the experience "brutal but worth it" during episodes in 2019 and 2020.
  • Ipamorelin: Publicly speculated based on his discussions about growth hormone secretagogues, but Rogan has not publicly confirmed ipamorelin use by name in a primary source the HealthRX.com Medical Team could verify.

The distinction matters. Rogan has been unusually transparent about TRT and HGH. For peptides like BPC-157 and NAD+, he has given first-person accounts. For ipamorelin specifically, the public record is thinner, and reporting it as confirmed would overstate what is documented.

Clinical Context: How TRT Works and What the Evidence Shows

Testosterone replacement therapy involves administering exogenous testosterone to men whose serum levels fall below the clinical reference range (typically <300 ng/dL on two morning draws, per the American Urological Association 2018 guidelines). Common delivery methods include intramuscular injection (testosterone cypionate or enanthate), transdermal gels, and subcutaneous pellets.

The hypothalamic-pituitary-gonadal (HPG) axis governs endogenous testosterone production. When exogenous testosterone is introduced, the hypothalamus detects elevated androgen levels and reduces GnRH secretion, which in turn suppresses LH and FSH from the anterior pituitary. This feedback loop is why TRT causes testicular atrophy and reduced spermatogenesis in most men, a point Rogan has acknowledged on air.

A 2016 New England Journal of Medicine trial (the Testosterone Trials, or TTrials) enrolled 790 men aged 65+ with low testosterone and found that one year of testosterone gel improved sexual function, walking distance, and mood compared to placebo. A 2010 meta-analysis in the Journal of Clinical Endocrinology & Metabolism covering 51 RCTs confirmed that TRT increases lean mass and reduces fat mass, with moderate effect sizes.

Standard dosing for testosterone cypionate runs 100 to 200 mg per week via intramuscular or subcutaneous injection. Most prescribing physicians target trough serum levels of 500 to 700 ng/dL, though some optimization-focused clinics aim higher.

Side Effects and Monitoring: What the Data Says

TRT is not risk-free. The clinical side effect profile includes:

  • Erythrocytosis (elevated hematocrit). The most common lab abnormality. A 2017 JAMA Internal Medicine study found hematocrit elevations above 54% in roughly 5 to 14% of men on TRT, depending on dose and delivery. Hematocrit above 54% raises venous thromboembolism risk and requires dose reduction or therapeutic phlebotomy.
  • Suppression of spermatogenesis. Exogenous testosterone suppresses FSH and intratesticular testosterone, both required for sperm production. This is reversible in most men after discontinuation, but recovery timelines vary from 3 to 12 months (Fertility and Sterility, 2019).
  • Acne and oily skin. Androgenic stimulation of sebaceous glands. Dose-dependent.
  • Cardiovascular signals. The TRAVERSE trial (NEJM, 2023), a large cardiovascular safety RCT, found that TRT did not significantly increase the incidence of major adverse cardiac events (MACE) in men aged 45 to 80 with hypogonadism and established or high risk for cardiovascular disease. This was the first adequately powered trial to address the question directly.
  • Sleep apnea exacerbation. Testosterone can worsen obstructive sleep apnea in susceptible individuals. The Endocrine Society's 2018 clinical practice guideline lists untreated severe sleep apnea as a contraindication.

Monitoring protocols typically include bloodwork at 3, 6, and 12 months after initiation, then annually. Standard panels: total and free testosterone, hematocrit/CBC, PSA, lipid panel, and hepatic function.

The Peptide and Longevity Layer

Rogan's public commentary extends well beyond testosterone. His podcast has aired extensive conversations about peptides, growth hormone, and NAD+ that reach an audience estimated at 11 million listeners per episode.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Animal studies show accelerated healing of tendons, ligaments, muscle, and gut tissue (Journal of Physiology, 2010). Human clinical trial data remains extremely limited. The FDA issued a warning letter in 2023 regarding compounding pharmacies marketing BPC-157 products, noting it has not been approved as a drug. Rogan has discussed using BPC-157 for joint recovery, but listeners should understand the regulatory and evidentiary gap between animal data and confirmed human efficacy.

NAD+ (nicotinamide adenine dinucleotide) IV infusions have gained popularity in the longevity space. NAD+ is a coenzyme central to mitochondrial energy metabolism. Preclinical data on NAD+ precursors like NMN and NR show promise for age-related decline (Science, 2017), but IV NAD+ infusions in humans lack large-scale RCT data. Rogan's description of the infusion as physically uncomfortable aligns with commonly reported side effects: nausea, chest tightness, and cramping during infusion.

HGH use in adults without documented growth hormone deficiency is off-label. The Endocrine Society's guidelines recommend GH replacement only for adults with biochemically confirmed deficiency. Side effects of exogenous GH include joint pain, carpal tunnel syndrome, insulin resistance, and fluid retention. Long-term safety data on GH use in non-deficient adults is sparse.

The HealthRX.com Medical Team Take

Joe Rogan has done something unusual for a public figure: he has been largely transparent about his hormone use, and he has paired that transparency with long-form clinical conversations featuring credentialed physicians and researchers. The HealthRX.com Medical Team views this as a net positive for health literacy, with caveats.

The positive: millions of men who would never read an endocrinology guideline have heard detailed explanations of the HPG axis, hematocrit monitoring, and the difference between TRT and anabolic steroid abuse. Rogan consistently frames his protocol as physician-supervised and bloodwork-driven.

The risk: the podcast format compresses nuance. A three-hour conversation with a longevity physician can leave listeners with the impression that TRT, HGH, BPC-157, and NAD+ are a standard "stack" any man should pursue. They are not. TRT is a medical intervention with a specific indication (hypogonadism), real side effects, and required monitoring. BPC-157 lacks human trial data. HGH in non-deficient adults is off-label with meaningful metabolic risks. NAD+ infusions remain clinically unproven at scale.

The HealthRX.com Medical Team recommends that any man considering TRT start with two fasting morning testosterone draws, a complete metabolic panel, and a conversation with a board-certified endocrinologist or urologist. Optimization clinics that prescribe testosterone after a single blood draw and a telehealth call may skip critical screening steps (sleep apnea evaluation, fertility counseling, cardiovascular risk stratification) that the Endocrine Society explicitly recommends.

Rogan's openness is commendable. The clinical infrastructure around the listener who hears that openness and decides to act on it needs to be equally rigorous.

At a glance

  • TRT status: Publicly confirmed by Joe Rogan on multiple podcast episodes over 10+ years
  • HGH status: Publicly confirmed
  • BPC-157 status: Publicly discussed as personal use for injury recovery
  • NAD+ infusions: Publicly confirmed
  • Ipamorelin: Publicly speculated, not confirmed by primary source
  • Clinical takeaway: TRT requires diagnosis, monitoring, and ongoing bloodwork; peptide protocols discussed by Rogan lack large human RCT data

Frequently asked questions

›
›
›
›
›

References

Take Our Free 2-min Assessment
Start now